Newsfile Corp
29 Jul 2026, 11:45 UTC · 13w ago
Impact · against what's priced in
CAPR faces a severe valuation collapse due to FDA briefing documents suggesting a lack of effectiveness for deramiocel and allegations of data manipulation. The potential for securities litigation further exacerbates the risk profile for both CAPR and TE.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA concluded that deramiocel's data did not provide substantial evidence of effectiveness and noted the application relied on only a single pivotal trial.
So whatThis directly threatens the approval of the company's primary cell therapy candidate, which is a fundamental driver of its valuation.
More negative than 99% of claims this week
Reports indicate Capricor made multiple changes to its statistical analysis plan after the study was completed, raising concerns about data manipulation to generate positive outcomes.
Continue reading
5 related stories
The FDA's conclusion that deramiocel lacked substantial evidence of effectiveness, coupled with allegations of post-hoc statistical changes, fundamentally undermines the company's primary asset.
Read from the article alone
No priced-in read yet
T1 Energy is facing a share price decline and a corresponding investigation by Block & Leviton for potential recovery of investor losses.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More negative than 98% of claims this week
Law firm Block & Leviton is investigating Capricor Therapeutics for potential securities law violations related to its regulatory representations.
More negative than 87% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company is under investigation for securities law violations following a 60% stock price drop and negative FDA briefing documents.
More negative than 81% of ticker scores this week
The article mentions that shares have dropped again and investors are encouraged to contact a law firm for potential recovery.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
15h ago
−2.9%
Price agrees with the score
$6.38 vs $6.57 close before publication (Jul 28) · not market-adjusted
CAPR chart →−34.9%
Price agrees with the score
$2.70 vs $4.15 close before publication (Jul 28) · not market-adjusted
TE chart →
